IMMUNORNASE FUSIONS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 338

8. Rybak SM, Arndt MA, Schirrmann T, Dubel S, Krauss J.
(2009) Ribonucleases and immunoRNases as anticancer
drugs. Curr. Pharm. Des. 15, 2665-2675.
9. Kreitman RJ. (2006) Immunotoxins for targeted cancer ther-
apy. AAPS J. 18, E532-551.
10. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. (2006) Immu-
notoxin therapy of cancer. Nat. Rev. Cancer 6, 559-565.
11. Frankel AE, Kreitman RJ, Sausville EA. (2000) Targeted
toxins. Clin. Cancer Res. 6, 326-334.
12. Kontermann RE. (2010) Alternative antibody formats. Curr.
Opin. Mol. Ther. 12, 176-183.
13. Vitetta ES. (2000) Immunotoxins and vascular leak syn-
drome. Cancer J. 6, 218-224.
14. Saxena SK, Rybak SM, Winkler G, Meade HM, McGray P,
Youle RJ, et al. (1991) Comparison of RNases and toxins
upon injection into Xenopus oocytes. J. Biol. Chem. 266,
21208-21214.
15. Rybak SM, Saxena SK, Ackerman EJ, Youle RJ. (1991)
Cytotoxic potential of ribonuclease and ribonuclease hybrid
proteins. J. Biol. Chem. 266, 21202-21207.
16. Leich F, Stohr N, Rietz A, Ulbrich-Hofmann R, Arnold U.
(2007) Endocytotic internalization as a crucial factor for the
cytotoxicity of ribonucleases. J. Biol. Chem. 282, 27640-
27646.
17. Ardelt W, Ardelt B, Darzynkiewicz Z. (2009) Ribonucleases
as potential modalities in anticancer therapy. Eur. J. Phar-
macol. 625, 181-189.
18. Ardelt W, Shogen K, Darzynkiewicz Z. (2008) Onconase 1
and Amphinase, the antitumor ribonucleases from Rana
pipiens oocytes. Curr. Pharm. Biotechnol. 9, 215-225.
19. Arnold U. (2008) Aspects of the cytotoxic action of ribonu-
cleases. Curr. Pharmacol. Biotechnol. 9, 161-168.
20. Lee JE, Raines RT. (2008) Ribonucleases as novel chemo-
therapeutics: the ranpirnase example. Biodrugs 22, 53-58.
21. Ramos-Nino ME. (2007) Cytotoxic ribonuclease-based can-
cer therapies. Drugs Fut. 32, 1-10.
22. Benito A, Ribo M, Vilanova M. (2005) On the track of
antitumor ribonucleases. Mol. Biosyst. 1, 294-302.
23. Saxena SK, Shogen K, Ardelt W. (2003) Onconase 1 and its
therapeutic potential. Lab. Med. 34, 380-387.
24. Makarov AA, Ilinskaya ON. (2003) Cytotoxic ribonucleases:
molecular weapons and their targets. FEBS Lett. 540, 15-20.
25. Leland PA, Raines RT. (2001) Cancer chemotherapy: ribo-
nucleases to the rescue. Chem. Biol. 8, 405-413.
26. Matousek J. (2001) Ribonucleases and their antitumor activ-
ity. Comp. Biochem. Physiol. C 129, 175-191.
27. Rybak SM, Newton DL. (1999) Natural and engineered
cytotoxic ribonucleases:

30. Dyer KD, Rosenberg HF. (2006) The RNase A superfamily:
generation of diversity and innate host defense. Mol. Divers.
10, 585-597.
31. Irie M. (1997) RNase T 1 /RNase T 2 family RNases. In:
D'Alessio G., Riordan JF. (Eds.), Ribonucleases: Structures
and Functions. Academic Press, San Diego, CA, pp. 101-130.
32. Rutkoski TJ, Raines RT. (2008) Evasion of ribonuclease
inhibitor as a determinant of ribonuclease cytotoxicity.
Curr. Pharm. Biotechnol. 9, 185-189.
33. Ardelt W, Mikulski SM, Shogen K. (1991) Amino acid
sequence of an anti-tumor protein from Rana pipiens oocytes
and early embryos. Homology to pancreatic ribonucleases. J.
Biol. Chem. 26, 245-251.
34. Marquez M, Nilsson S, Lennartsson L, Liu Z, Tammela T,
Raitanen M, et al. (2004) Charge-dependent targeting:
results in six tumor cell lines. Anticancer Res. 24, 1347-
1351.
35. Haigis MC, Raines RT. (2003) Secretory ribonucleases are
internalized by a dynamin-independent endocytic pathway.
J. Cell Sci. 116(Pt 2), 313-324.
36. Rodriguez M, Torrent G, Bosch M, Dubremetz J-F, Ribo M,
Benito A, et al. (2007) Intracellular pathway of Onconase 1
that enables its delivery to the cytosol. J. Cell Sci. 120, 1405-
1411.
37. Benito A, Vilanova M, RiboM. (2008) Intracellular routing of
cytotoxic pancreatic-type ribonucleases. Curr. Pharm. Bio-
technol. 9, 169-179.
38. Boix E, Wu Y-N, Vasandani VM, Saxena SK, Ardelt W,
Ladner J, et al. (1996) Role of the N-terminus in RNase A
homoloques: differences in catalytic activity, ribonuclease
inhibitor interaction and cytotoxicity. J. Mol. Biol. 257,
992-1007.
39. Kelemen BR, Klink TA, Behlke MA, Eubanks SR, Leland
PA, Raines RT. (1999) Hypersensitive substrates for ribonu-
cleases. Nucleic Acids Res. 27, 3696-3701.
40. Turcotte RF, Raines RT. (2008) Interaction of Onconase 1
with the human ribonuclease inhibitor protein. Biochem.
Biophys. Res. Commun. 377, 512-514.
41. Juan G, Ardelt B, Mikulski SM, Shogen K, Ardelt W, Mittel-
man A, et al. (1998) G 1 arrest of U-937 cells by Onconase 1 is
associated with suppression of cyclin D3 expression, induc-
tion of p16 INK4A, p21 WAF1/CIP1 and p27 KIP and decreased pRb
phosphorylation. Leukemia 12, 1241-1248.
42. Altomare DA, Rybak SM, Pei J, Maizel JV, Cheung M, Testa
JR, et al. (2010) Onconase 1 responsive genes in human
mesothelioma cells: implications for an RNA damaging
therapeutic agent. BMC Cancer 10, 34.
43. Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen
K, Youle RJ. (2002) Entry into cells and selective degradation
of tRNAs by a cytotoxic member of the RNase A family. J.
Biol. Chem. 277, 15142-15146.
44. Suhasini AN, Sirdeshmukh R. (2006) Transfer RNA cleav-
ages by Onconase 1 reveal unusual cleavage sites. J. Biol.
Chem. 281, 12201-12209.
45. Ardelt B, Ardelt W, Darzynkiewicz Z. (2003) Cytotoxic
ribonucleases and RNA interference. Cell Cycle 2, 22-24.

therapeutic potential. Exp. Cell

Res. 253, 325-335.
28. Youle RJ, D'Alessio G. (1997) Antitumor RNases. In:
D'Alessio G, Riordan JF. (Eds.), Ribonucleases: Structures
and Functions. Academic Press, San Diego, CA 491-514.
29. Beintema JJ, Schuller C, Irie M, Carsana A. (1988) Molecular
evolution of the ribonuclease superfamily. Prog. Biophys.
Mol. Biol. 151, 165-192.